Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2492452 | 0.99 | KMT2A (0.51) | KMT2AMEN1RXFP1CA1CA2 | |
| SCHEMBL9967272 | 0.84 | RAB9A (0.45) | KMT2AMEN1MAPTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL2492465 | 0.83 | RAB9A (0.44) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL9967270 | 0.83 | RAB9A (0.59) | KMT2AMEN1MAPT | |
| SCHEMBL9970767 | 0.82 | ALDH1A1 (0.44) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL9970757 | 0.82 | POLB (0.51) | KMT2AMEN1POLBRECQLALDH1A1 | |
| SCHEMBL1458631 | 0.82 | HPGD (0.47) | KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL1459729 | 0.82 | PTPN1 (0.54) | KMT2AMEN1MAPTPOLB | |
| Hydrochloric Acid SCHEMBL2495647 | 0.82 | POLB (0.50) | KMT2AMEN1POLBRECQLALDH1A1 | |
| Hydrochloric Acid SCHEMBL2492460 | 0.81 | ALDH1A1 (0.43) | KMT2AMEN1MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-9867812-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160310474-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2016-10-27 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-9227964-B2 | N-biarylamides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-05 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20140288118-A1 | N-BIARYLAMIDES | BAYER INTELLECTUAL PROPERTY GMBH | 2014-09-25 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157490-A1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030329-B2 | N-biarylamides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7354930-B2 | N-biarylamides | BAYER HEALTHCARE AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1651645-B1 | N-BIARYLAMIDES | BAYER HEALTHCARE AG (DE) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112023-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement | CHRNA7, CHRNA3, CHRNA5 | KMT2A 2509/4885MEN1 4500/4885RXFP1 1043/4885 |
| US-20140288118-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | KMT2A 737/4885MEN1 2378/4885RXFP1 4725/4885 |
| US-20120157490-A1 | N-BIARYLAMIDES | GRIN2A, BCHE, ACHE | KMT2A 1435/4885MEN1 3205/4885RXFP1 4078/4885 |
| US-20160310474-A1 | N-BIARYLAMIDES | BCHE, BACE2, ACHE | KMT2A 737/4885MEN1 2378/4885RXFP1 4725/4885 |
| US-20080214602-A1 | (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine--3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, learning and perception enhancement | CHRNA7, CHRNA3, CHRNA2 | KMT2A 1232/4885MEN1 4712/4885RXFP1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.